Shoblock James R, Sullivan Eric B, Maisonneuve Isabelle M, Glick Stanley D
Center for Neuropharmacology and Neuroscience, Albany Medical College, 47 New Scotland Avenue (MC-136), Albany, NY 12208, USA.
Psychopharmacology (Berl). 2003 Feb;165(4):359-69. doi: 10.1007/s00213-002-1288-7. Epub 2002 Dec 19.
Methamphetamine (METH) and amphetamine (AMPH) are both abused psychostimulants. Although METH is generally accepted to be more addictive and potent than its analogue AMPH, there are no known neurobiological differences in action between the two drugs that may account for such differences.
METH and AMPH were compared to determine potential mechanisms for such differences between the two drugs in order to provide new targets for the treatment of METH addiction.
Using in vivo microdialysis on rats, dopamine (DA), DA metabolites, and glutamate (GLU) release in the nucleus accumbens (NAC) and prefrontal cortex (PFC) were measured after administration of 2 mg/kg, IP, of METH or AMPH. Based on the neurochemical differences between METH and AMPH, a locomotor activity study was designed to assess differences in locomotor activation for a range of doses (1-4 mg/kg, IP) of METH and AMPH and after pretreatment with intra-accumbens GLU antagonists.
METH and AMPH raised NAC DA levels to a similar degree. In the PFC, both METH and AMPH raised DA levels, but METH was less effective than AMPH. In the NAC, AMPH raised GLU levels but METH did not. In the PFC, METH raised GLU levels but AMPH did not. The locomotor activity dose response curve for METH had a lower peak than that of AMPH. This difference was blocked by pretreatment with either the GLU NMDA antagonist AP5 or the GLU AMPA antagonist DNQX locally in the NAC.
This study reveals several previously unknown neurochemical and behavioral differences between METH and AMPH. Based on these results, it is suggested that new pharmacotherapeutic agents that produce augmentations of NAC GLU or PFC DA activity, or perhaps inhibition of PFC GLU activity, may someday be useful for the treatment of METH addiction.
甲基苯丙胺(METH)和苯丙胺(AMPH)都是被滥用的精神兴奋剂。尽管一般认为METH比其类似物AMPH更具成瘾性和效力,但目前尚不清楚这两种药物在作用上有哪些神经生物学差异可以解释这种不同。
比较METH和AMPH,以确定这两种药物之间存在这种差异的潜在机制,从而为治疗METH成瘾提供新的靶点。
对大鼠进行体内微透析,在腹腔注射2mg/kg的METH或AMPH后,测量伏隔核(NAC)和前额叶皮质(PFC)中多巴胺(DA)、DA代谢产物和谷氨酸(GLU)的释放。基于METH和AMPH之间的神经化学差异,设计了一项运动活动研究,以评估一系列剂量(1-4mg/kg,腹腔注射)的METH和AMPH以及在伏隔核内注射GLU拮抗剂预处理后的运动激活差异。
METH和AMPH使NAC中的DA水平升高程度相似。在PFC中,METH和AMPH都使DA水平升高,但METH的效果不如AMPH。在NAC中,AMPH使GLU水平升高,但METH没有。在PFC中,METH使GLU水平升高,但AMPH没有。METH的运动活动剂量反应曲线的峰值低于AMPH。这种差异可通过在NAC局部预先使用GLU NMDA拮抗剂AP5或GLU AMPA拮抗剂DNQX来阻断。
本研究揭示了METH和AMPH之间一些以前未知的神经化学和行为差异。基于这些结果,建议未来可能会有新的药物治疗剂,可增强NAC的GLU或PFC的DA活性,或者可能抑制PFC的GLU活性,从而用于治疗METH成瘾。